No Data
Is Weakness In Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
Jumpcan Pharma's Unit Gets Nod for Roxadustat Capsules' Registration
Hubei Jumpcan Pharmaceutical (600566.SH): has cumulatively repurchased 0.02% of shares.
Gelonghui, January 3 - Hubei Jumpcan Pharmaceutical (600566.SH) announced that as of December 31, 2024, the company has repurchased a total of 180,500 shares through centralized competitive trading, accounting for 0.02% of the company's total share capital. The highest purchase price was 29.00 yuan per share, the lowest was 27.29 yuan per share, and the total amount paid was 5,004,978 yuan (excluding transaction fees).
Are Investors Undervaluing Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) By 47%?
Hubei Jumpcan Pharmaceutical Gets China Approval for Antibiotics
Hubei Jumpcan Pharmaceutical (600566.SH): Subsidiary obtained the Pharmaceutical registration certificate.
On December 12, Gelonghui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Hubei Jumpcan Pharmaceutical Group Co., Ltd., and Shaanxi Dongke Pharmaceutical Co., Ltd. received the pediatric Faropenem sodium granule "Drug Registration Certificate" and the injectable Cefoperazone Sodium "Drug Registration Certificate" approved by the National Medical Products Administration. The registration of pediatric Faropenem sodium granules is classified as Chemical Drug Class 4, and it was reviewed and approved in accordance with the technical requirements consistent with the quality and efficacy of the reference preparation. Once approved, it is regarded as having passed the consistency evaluation of the quality and efficacy of generic drugs, mainly used for treating pediatric infectious diseases caused by bacteria sensitive to Faropenem.
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
